<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000600013</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i6.2022</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Actualidades en el tratamiento farmacológico a largo plazo de la obesidad. ¿Una opción terapéutica?]]></article-title>
<article-title xml:lang="en"><![CDATA[Up-to-date in the long-term pharmacological treatment of obesity. A therapeutic option?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alarcón-Sotelo]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Romero]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Regules-Silva]]></surname>
<given-names><![CDATA[Sonia De]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pardinas-Llergo]]></surname>
<given-names><![CDATA[María José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Weber]]></surname>
<given-names><![CDATA[Federico L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Greene]]></surname>
<given-names><![CDATA[Enrique J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Nacional 20 de Noviembre  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad La Salle  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Ángeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Ángeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Ángeles Pedregal  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>6</numero>
<fpage>946</fpage>
<lpage>958</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000600013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000600013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000600013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La obesidad es una enfermedad crónica, con afección sistémica y de carácter multifactorial que constituye un grave problema de salud pública, considerada por la Organización Mundial de la Salud una epidemia global. La obesidad es resultado del equilibrio energético positivo por tiempo prolongado, donde la energía derivada de los alimentos excede la energía gastada en la vida cotidiana. En vía de poner fin a este problema de salud pública se han buscado opciones de tratamiento, si bien las modificaciones al estilo de vida, incluida la dieta y el ejercicio, siguen siendo la piedra angular del tratamiento de la obesidad, estas modificaciones no han permitido mantener resultados a largo plazo, por esta razón los medicamentos contra la obesidad se vuelven una opción viable. Son cinco los medicamentos aprobados por la Dirección de Alimentos y Fármacos de Estados Unidos para el tratamiento a largo plazo de la obesidad: orlistat, fentarmina/topiramato de liberación prolongada, lorcarserina, naltrexona/bupropión de liberación prolongada y liraglutida, mismos que han demostrado eficacia y seguridad necesaria para tomarse en cuenta como una opción terapéutica. En este artículo revisaremos la eficacia y seguridad de cada uno los medicamentos aprobados contra la obesidad que se encuentran disponibles.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Obesity is a chronic disease, with systemic affection and of multifactorial character that constitutes a serious problem of public health, being considered by the World Health Organization a global epidemic. Obesity is the result of a positive energy balance by a long time, where the energy derived from food exceeds the energy expended in everyday life. In order to put an end to this public health problem, treatment options have been sought, although the modifications to the lifestyle included diet and exercise are still the cornerstone of the treatment for obesity, these modifications have not allowed to maintain long-term results; for this reason anti-obesity drugs become a viable option. There are five drugs approved by the FDA nowadays for the long-term treatment of obesity: orlistat, phentermine/topiramate prolonged release, lorcarserin, naltrexone/bupropion prolonged release, and liraglutide, which have shown efficacy and the necessary safety to be taken into account as a therapeutic option. In this article we will review the effectiveness and safety of each of the approved anti-obesity drugs that are available.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Obesidad]]></kwd>
<kwd lng="es"><![CDATA[sobrepeso]]></kwd>
<kwd lng="es"><![CDATA[medicamentos contra la obesidad]]></kwd>
<kwd lng="es"><![CDATA[pérdida de peso]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Overweight]]></kwd>
<kwd lng="en"><![CDATA[Antiobesity drugs]]></kwd>
<kwd lng="en"><![CDATA[Weight loss]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<source><![CDATA[Diagnóstico, Tratamiento y Prevención de Sobrepeso y Obesidad en el Adulto]]></source>
<year></year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud. Actualización 2012]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Global status report on non-communicable diseases 2014]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[NB.]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[L. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoo]]></surname>
<given-names><![CDATA[E. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ethier]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
</person-group>
<collab>Centers for Disease Control and Prevention (CDC)</collab>
<source><![CDATA[CDC National Health Report Leading causes of morbidity and mortality and associated behavioral risk and protective factors-United States]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on obesity pharmacotherapy]]></article-title>
<source><![CDATA[Ann NY Acad Sci]]></source>
<year>2014</year>
<volume>131</volume>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición de Medio Camino 2016]]></source>
<year>2016</year>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Salud Pública</collab>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 Informe Final de Resultados]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erlanger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Henson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification and Pharmacological Management of Obesity]]></article-title>
<source><![CDATA[P&amp;T]]></source>
<year>2008</year>
<volume>33</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>724-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Macie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thabane]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of long-term weight loss studies in obese adults clinical significance and applicability to clinical practice]]></article-title>
<source><![CDATA[Int J Obes]]></source>
<year>2005</year>
<volume>29</volume>
<page-range>1153-67</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moyer]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for and management of obesity in adults U.S. preventive services task force recommendation]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>157</volume>
<page-range>373-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ayyad]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy of dietary treatment of obesity a systematic review of studies published between 1931 and 1999]]></article-title>
<source><![CDATA[Obes Rev]]></source>
<year>2000</year>
<volume>1</volume>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Apovian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>129</volume>
<page-range>S102-38</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickett]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Newberry]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Future Therapies in Obesity]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>2016</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>705-14</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Minnion]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of gut hormones and the hypothalamus in appetite regulation]]></article-title>
<source><![CDATA[Endocr J]]></source>
<year>2010</year>
<volume>57</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>359-72</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Billington]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>2004</year>
<volume>1018</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-85</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mietlicki-Baase]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ortinski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rupprecht]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors]]></article-title>
<source><![CDATA[Am J Physiol Endocrinol Metab]]></source>
<year>2013</year>
<volume>305</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>E1367-74</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Virtanen]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Lidell]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Orava]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Functional brown adipose tissue in healthy adults]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>360</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1518-25</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tseng]]></surname>
<given-names><![CDATA[Y-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic control of brown fat thermogenesis integration of peripheral and central signals]]></article-title>
<source><![CDATA[Ann NY Acad Sci]]></source>
<year>2013</year>
<volume>1302</volume>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bloom]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The new era of drug therapy for obesity The evidence and the expectations]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2005</year>
<volume>75</volume>
<page-range>935-45</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<collab>Look AHEAD Research Group</collab>
<article-title xml:lang=""><![CDATA[Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes a secondary analysis of the Look AHEAD randomised clinical trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2014</year>
<volume>2</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>801-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bartels]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Astrup]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bliddal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of weight reduction in obese patients diagnosed with knee osteoarthritis a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2007</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>433-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Crary]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McGoon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valvular heart disease associated with fenfluramine-phentermine]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>337</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>581-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rolls]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shide]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thorwart]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Ulbrecht]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sibutramine reduces food intake in non-dieting women with obesity]]></article-title>
<source><![CDATA[Obes Res]]></source>
<year>1998</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Caterson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Coutinho]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>905-17</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sweeting]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hocking]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy for the treatment of obesity]]></article-title>
<source><![CDATA[Molecular and Cellular Endocrinology]]></source>
<year>2015</year>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alamuddin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bakizada]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Obesity]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2016</year>
<volume>34</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>4295-305</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and Management of weight loss]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1187-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Varayil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New pharmacological treatments for the management of obesity]]></article-title>
<source><![CDATA[Curr Gastroenterol Rep]]></source>
<year>2014</year>
<volume>16</volume>
<numero>394</numero>
<issue>394</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Togerson]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Haupman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boldrin]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In the prevention of diabetes in obese subject (XENDOS) study; a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patient]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>155-61</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Meara]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Riemsma]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Shirran]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systemic review of the clinical effectiveness of orlistat used for the management of obesity]]></article-title>
<source><![CDATA[Obes Rev]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>51-68</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacob]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rabbia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Hauptman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2009</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>361-71</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Derosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maffioli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-obesity drugs a review about their effects and their safety]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2012</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>459-71</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keith]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy in treatment of obesity]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>2016</year>
<volume>45</volume>
<page-range>663-72</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanibuddin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Humaira]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological Management of obesity Past, present and future]]></article-title>
<source><![CDATA[Saudi J Obesity]]></source>
<year>2014</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-12</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Blomain]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Waldman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiobesity pharmacotherapy New drugs and emerging targets]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2014</year>
<volume>95</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-66</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weissman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter, placebo-controlled trial of lorcaserin for weight management]]></article-title>
<collab>Anderson C et al</collab>
<source><![CDATA[New J Med]]></source>
<year>2010</year>
<volume>363</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>245-56</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fidles]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Raether]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A one year randomized trial of lorcaserin for weight loss in obese and overweight adults The BLOSSOM Trial]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2011</year>
<volume>96</volume>
<page-range>3067-77</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Neil]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Weissman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus the BLOOM- DM study]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2012</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1426-36</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Butsch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity medications what does the future look like?. Curr Opin Endocrinol Diabetes]]></article-title>
<source><![CDATA[Obes]]></source>
<year>2015</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>360-6</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umashanker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Igel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current and future medical treatment of obesity]]></article-title>
<source><![CDATA[Gastrointest Endoscopy Clin N Am]]></source>
<year>2017</year>
<volume>27</volume>
<page-range>181-90</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current pharmacotherapy for obesity extrapolation of clinical trials to practice]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2014</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>809-22</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER) a randomized, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>16</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>1341-52</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gadde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlled-release phentermine/topiramate in severely obese adults a randomized controlled trial (EQUIP)]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2012</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>330-42</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Look]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL) a randomized, placebo-controlled, phase 3 extension study]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2012</year>
<volume>95</volume>
<page-range>297-308</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadde]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Raj]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy of obesity Clinical trials to clinical practice]]></article-title>
<source><![CDATA[Curr Diab Rep]]></source>
<year>2017</year>
<volume>17</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Frühbeck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of obesity]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<numero>10031</numero>
<issue>10031</issue>
<page-range>1974-56</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Fujioka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Plodkowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I) a multicenter, randomized double-blind, placebo-controlled, phase 3 trial]]></article-title>
<collab>COR-I Study Group</collab>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<page-range>595-605</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Foreyt]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification the COR-BMOD trial]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2011</year>
<volume>19</volume>
<page-range>110-20</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Apovian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)]]></article-title>
<source><![CDATA[Obesity]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>935-43</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollander]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Plodkowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>4022-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wolski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Prcela]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>315</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>990-1004</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Astrup]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carraro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Finer]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide]]></article-title>
<source><![CDATA[Int J Obes]]></source>
<year>2012</year>
<volume>36</volume>
<page-range>843-54</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wadden]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hollander]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss the SCALE Maintenance randomized study]]></article-title>
<source><![CDATA[Int J Obes]]></source>
<year>2013</year>
<volume>37</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1443-251</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pi-Sunyer]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Astrup]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fujioka]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, controlled trial of 3 0 mg of liraglutide in weight management]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-22</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Douketis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2007</year>
<volume>176</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-117</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="confpro">
<collab>The National Institute for Health and Care Excellence</collab>
<source><![CDATA[Obesity: identification assessment and management (CG 189)]]></source>
<year></year>
<conf-name><![CDATA[ NICE]]></conf-name>
<conf-date>2014</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yumuk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tsigos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European guidelines for obesity management in adults]]></article-title>
<source><![CDATA[Obes Facts]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>402-24</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<collab>AACE/ACE Guidelines American Association of Clinical Endocrinologists and American college of endocrinology</collab>
<article-title xml:lang=""><![CDATA[Clinical practice guidelines for comprehensive medical care of patients with obesity]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2016</year>
<volume>22</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>1-203</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guillemin]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Barnard]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[George Libman Engel: The Biopsychosocial Model and the Construction of Medical Practice]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Collyer]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Palgrave Handbook of Social Theory in Health, Illness and Medicine]]></source>
<year>2015</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave Macmillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenneth]]></surname>
<given-names><![CDATA[E F]]></given-names>
</name>
</person-group>
<collab>Freedland Washington University School of Medicine</collab>
<article-title xml:lang=""><![CDATA[A new era for health psychology]]></article-title>
<source><![CDATA[Health Psychology]]></source>
<year>2017</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
